Have you done any of the looking at historical rates of ORR in such a highly refractory population?
If you are not counting GNMBP status then I can find very similar trials, and that is were I guessed 5% from.
I have no clue at all about how G+ selection would affect this. I do see cites that it is associated with outcomes (G+ has worse outcomes), but no sites on ORR.
EDIT: The Eribulan P3 trial was close in patient pool, and the comparator arm ORR was 5%.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.